surpass 2 tirzepatide versus Semaglutide in Type Diabetes (SURPASS-2) | NEJM Tirzepatide versus Semaglutide Once Weekly

The key message is clear: these treatments are powerful, but their long-term public health impact will depend on whether the right support systems are in place to ensure equitable and safe access for all patients. This comes as a new semaglutide 7.2mg single-dose pen has been launched by Novo Nordisk as a maintenance dose for adults with obesity, following approval from the Medicines and Healthcare products Regulatory Agency

Enoch, H

These medications are generally well-tolerated, but the most common side effects include nausea, diarrhea, and sometimes mild indigestion

Mounjaro is FDA-approved for managing blood sugar levels in adults with type 2 diabetes mellitus, and Zepbound is indicated for weight loss in patients with obesity and overweight with at least one weight-related health condition (high blood pressure or high cholesterol level) and mild to moderate obstructive sleep apnea

It signals the brain to reduce appetite, tells the stomach to slow digestion so you feel fuller longer, and helps the pancreas regulate blood sugar

This all goes hand-in-hand with anti-aging benefits and overall general improved levels of wellbeing